Virus-based treatment for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new virus-based treatment for advanced melanoma that has spread to the brain or other parts of the body. The virus is injected directly into a tumor to try to kill it, and it may boost your immune system against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have stage IV melanoma.
- You must be able to care for yourself (ECOG score 0 or 1).
- You must be on a standard immunotherapy (like nivolumab or pembrolizumab).
- You must have either 1–5 brain tumors (Group A) or a skin/lymph node tumor that can be injected (Group B), and your overall cancer may be stable or growing.
- You must be able to have an MRI with contrast and, if in Group A, agree to a biopsy of a brain tumor.
- You must not have certain health issues (uncontrolled infections, bleeding risks, other serious illnesses) or be pregnant/breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.